Retrospective Analysis of Drug Sensitivity of Neisseria gonorrhoeae in Teaching Hospitals of South China

Figures & data

Table 1 Antimicrobial Resistance to Neisseria gonorrhoeae Infection from 2016 to 2020

Year	Gender	Age	Antimicrobial Resistance (%)
			Penicillin	Cefuroxime	Cefepime	Ciprofloxacin	Ceftazidime	Spectinomycin	Ceftriaxone	Azithromycin
2016	M41, F6	29.82±7.00	44.68	14.89	19.15	87.23	12.77	8.51	6.38	6.38
2017	M59, F3	28.88±7.46	61.29	12.90	16.13	93.55	10.84	8.06	8.06	9.68
2018	M76, F3	29.41±8.41	37.97	15.40	15.63	75.95	13.63	5.06	8.86	10.13
2019	M59, F3	30.39±10.88	46.43	17.85	19.64	91.07	10.71	8.71	14.29	12.50
2020	M56, F4	34±11.05	66.67	10.00	16.67	90.00	13.67	6.67	11.67	16.67

Abbreviations: M, male; F, female.

Table 2 Neisseria gonorrhoeae Infection in Teaching Hospitals from 2016 to 2020

Year	Gender	Age	β-lactamase Positive	Chlamydia Antigen Positive	Ureaplasma urealyticum Positive	Mycoplasma hominis Positive	GC+ Chlamydia+ UU Positive	GC+ Chlamydia+ Mh Positive	GC+ Chlamydia+ UU+ Mh Positive
2016	M41, F6	29.82±7.00	42.55%	13.40%	7.02%	6.38%	8.33%	1.67%	1.67%
2017	M59, F3	28.88±7.46	40.32%	12.90%	9.68%	6.45%	8.93%	3.57%	1.79%
2018	M76, F3	29.41±8.41	48.10%	16.46%	10.13%	6.33%	7.60%	2.53%	2.53%
2019	M59, F3	30.39±10.88	67.86%	21.42%	14.29%	7.36%	8.06%	4.84%	3.22%
2020	M56, F4	34±11.05	68.33%	28.33%	17.00%	6.67%	12.77%	4.26%	4.26%

Abbreviations: M, male; F, female; GC, Neisseria gonorrhoeae; UU, Ureaplasma urealyticum; Mh, Mycoplasma hominis.